Literature DB >> 20548011

Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?

Mona Saraiya1, Zahava Berkowitz, K Robin Yabroff, Louise Wideroff, Sarah Kobrin, Vicki Benard.   

Abstract

BACKGROUND: Guidelines recommend screening for cervical cancer among women 30 years or older 3 years after a normal Papanicolaou test (hereinafter referred to as Pap test) result or a combined normal screening result (normal Pap/negative human papillomavirus [HPV] test results). We assessed reported recommendations by US primary care physicians (PCPs) on screening intervals that incorporate HPV cotesting compared with Pap testing alone.
METHODS: From September 1, 2006, through May 31, 2007, we conducted a mailed survey of a representative sample of 1212 PCPs, of whom 950 performed Pap tests and recommended the HPV test for screening or management. The main outcome measure included self-reported data on timing of screening intervals for women with normal results using clinical vignettes.
RESULTS: Among Pap test providers who recommend HPV testing, 31.8% reported that they would conduct the next Pap test in 3 years for a 35-year-old woman with 3 normal Pap test results. For a 35-year-old woman with a normal Pap test result and a negative HPV test finding, only 19.0% would conduct the next Pap test in 3 years. Most remaining physicians would conduct the Pap test more frequently. Most PCPs did not recommend a second HPV test or recommended the next HPV test at the same frequency as the Pap test. Physician specialty was strongly associated with guideline-consistent recommendations for the next Pap or HPV test.
CONCLUSIONS: A lower proportion of PCPs recommend extending screening intervals to 3 years with an HPV cotest than those screening with the Pap test alone. Implementation of effective interventions and strategies that improve physician adherence to recommendations will be important for efficient screening practices.

Entities:  

Mesh:

Year:  2010        PMID: 20548011     DOI: 10.1001/archinternmed.2010.134

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  44 in total

1.  Use of electronic health record data to evaluate overuse of cervical cancer screening.

Authors:  Jason S Mathias; Dana Gossett; David W Baker
Journal:  J Am Med Inform Assoc       Date:  2012-01-19       Impact factor: 4.497

Review 2.  Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Authors:  Vikrant V Sahasrabuddhe; Patricia Luhn; Nicolas Wentzensen
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

3.  Performance of implementing guideline-driven cervical cancer screening measures in an inner-city hospital system.

Authors:  Daryl L Wieland; Laura L Reimers; Eijean Wu; Lisa M Nathan; Tammy Gruenberg; Maria Abadi; Mark H Einstein
Journal:  J Low Genit Tract Dis       Date:  2011-10       Impact factor: 1.925

Review 4.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

5.  Adherence to conservative management recommendations for abnormal pap test results in adolescents.

Authors:  Rebecca B Perkins; Jennifer R Jorgensen; Molly E McCoy; Sharon M Bak; Tracy A Battaglia; Karen M Freund
Journal:  Obstet Gynecol       Date:  2012-06       Impact factor: 7.661

6.  Overview of the CDC Cervical Cancer (Cx3) Study: an educational intervention of HPV testing for cervical cancer screening.

Authors:  Vicki B Benard; Mona Saraiya; April Greek; Nikki A Hawkins; Katherine B Roland; Diane Manninen; Donatus U Ekwueme; Jacqueline W Miller; Elizabeth R Unger
Journal:  J Womens Health (Larchmt)       Date:  2013-12-31       Impact factor: 2.681

7.  Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers.

Authors:  Nikki A Hawkins; Vicki B Benard; April Greek; Katherine B Roland; Diane Manninen; Mona Saraiya
Journal:  Prev Med       Date:  2013-09-05       Impact factor: 4.018

8.  Human papillomavirus (HPV) testing for normal cervical cytology in low-risk women aged 30-65 years by family physicians.

Authors:  Maria Syl D de la Cruz; Alisa P Young; Mack T Ruffin
Journal:  J Am Board Fam Med       Date:  2013 Nov-Dec       Impact factor: 2.657

9.  Cervical cancer screening in the United States and the Netherlands: a tale of two countries.

Authors:  Dik Habbema; Inge M C M De Kok; Martin L Brown
Journal:  Milbank Q       Date:  2012-03       Impact factor: 4.911

10.  Cervical carcinoma rates among young females in the United States.

Authors:  Vicki B Benard; Meg Watson; Philip E Castle; Mona Saraiya
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.